A federal appeals court on Friday granted a request from the state of Louisiana to reinstate a nationwide requirement that abortion pills be dispensed in person. This ruling blocks the ability of patients to obtain mifepristone, one of two medications used in medication abortions, via mail or telehealth services.
Impact on Medication Access
The decision is viewed as a victory for opponents of abortion rights because it limits access to medication abortions. Telehealth prescriptions have been essential for maintaining access in states that restricted or outlawed the practice following the 2022 Supreme Court decision to overturn Roe v. Wade.
Medication abortion is a primary method of termination, accounting for more than half of all abortions in the United States. Peer-reviewed research and multiple studies have indicated that these medications are safe and effective when taken at home after a clinician consultation, noting that serious adverse reactions are rare.
The Legal Challenge
The dispute centers on a Food and Drug Administration (FDA) regulation. During the Covid pandemic, the FDA under President Joe Biden temporarily removed the requirement that mifepristone be dispensed only in hospitals, medical offices, and clinics; this change became permanent in 2023.
Louisiana challenged the regulation last year, alleging that the data supporting the change was nonexistent or flawed and that the policy created safety risks. While a district court judge previously denied Louisiana’s request to reinstate in-person requirements, the Fifth Circuit Court of Appeals reversed that decision on Friday.
Circuit Judge Stuart Kyle Duncan wrote that the FDA’s telehealth provision injures Louisiana by undermining state laws protecting unborn human life. He further stated that the provision causes the state to spend Medicaid funds on emergency care for women harmed by mifepristone, describing both injuries as irreparable.
Reactions from Health and Legal Advocates
Julia Kaye, a senior staff attorney for the Reproductive Freedom Project of the ACLU, stated Friday that anti-abortion politicians have made it much harder for patients to access a medication that has been used safely for more than 25 years.
Evan Masingill, CEO of GenBioPro, a manufacturer of generic mifepristone, expressed alarm that the court ignored rigorous science and decades of safe use. Meanwhile, Alexis McGill Johnson, CEO of Planned Parenthood Action Fund, stated that their health centers remain committed to providing care where it is legal.
Conversely, Louisiana Attorney General Liz Murrill, who filed the suit alongside Alliance Defending Freedom, said she looks forward to continuing to defend women and babies. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, called the ruling a huge victory against what she termed a reckless mail-order drug regime.
Potential Next Steps
The legal battle may continue as the parties review the court’s order. In January, the FDA had requested that the lawsuit be paused until the Trump administration completed its own safety review of mifepristone.
Because Louisiana has some of the nation’s harshest restrictions, including bans without exceptions for incest or rape, the reinstatement of in-person requirements could further restrict access within the state. However, some providers may still attempt to use shield laws to protect those prescribing pills to patients in states where abortion is banned.
Frequently Asked Questions
What is mifepristone?
Mifepristone is one of two pills used in medication abortions.
Why did Louisiana challenge the FDA regulation?
Louisiana alleged that the FDA’s telehealth provision created safety risks and that the data used to support the regulation was flawed or nonexistent.
What was the court’s reasoning for granting the stay?
Circuit Judge Stuart Kyle Duncan stated that the telehealth provision undermines Louisiana’s laws protecting unborn human life and causes the state to spend Medicaid funds on emergency care for women harmed by the drug.
How do you believe nationwide dispensing requirements will affect healthcare access in restrictive states?